Galapagos (GLPG) Downgraded to Sell at ValuEngine
Galapagos (NASDAQ:GLPG) was downgraded by equities researchers at ValuEngine from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Friday.
A number of other research analysts have also commented on the stock. Nomura raised their price objective on shares of Galapagos from $108.00 to $124.00 and gave the company a “buy” rating in a research note on Friday, August 11th. BidaskClub upgraded shares of Galapagos from a “sell” rating to a “hold” rating in a report on Thursday, August 17th. Stifel Nicolaus restated a “buy” rating and set a $120.00 target price on shares of Galapagos in a report on Sunday, October 29th. Morgan Stanley restated an “overweight” rating and set a $123.00 target price (up from $92.00) on shares of Galapagos in a report on Friday, October 6th. Finally, Royal Bank Of Canada started coverage on shares of Galapagos in a report on Thursday, September 14th. They set a “sector perform” rating and a $98.00 target price for the company. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the company. Galapagos currently has a consensus rating of “Hold” and a consensus price target of $111.00.
Galapagos (GLPG) traded down $0.93 during midday trading on Friday, hitting $87.25. 86,505 shares of the company were exchanged, compared to its average volume of 76,725. Galapagos has a fifty-two week low of $57.86 and a fifty-two week high of $104.12.
COPYRIGHT VIOLATION NOTICE: “Galapagos (GLPG) Downgraded to Sell at ValuEngine” was first posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/12/03/galapagos-glpg-downgraded-to-sell-at-valuengine.html.
Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related companies with MarketBeat.com's FREE daily email newsletter.